Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

I am a UK healthcare professional No, take me back
UK-RES-2101606 August 2021

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2101574 August 2021

INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY
Overview
Dosing & Device

Costing

Evidence

Prescribing Information

General Resources

Fostair in COPD

The following Fostair presentations can be used for the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) each delivering 120 inhalations per device.1,2
  • Fostair NEXThaler 100/6
  • Fostair pMDI 100/6
Fostair® NEXThaler and pMDI devices
The following Fostair presentations can be used for the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) each delivering 120 inhalations per device.1,2
  • Fostair NEXThaler 100/6
  • Fostair pMDI 100/6
Comparable efficacy
  • Fostair NEXThaler has demonstrated comparable efficacy to Fostair pMDI across a variety of lung function measures1
  • Both Fostair pMDI and Fostair NEXThaler are characterised by an extrafine particle size distribution1,2

Fostair‘s extrafine particle size distribution results in a more potent effect than formulations of beclometasone with a non-extrafine particle size distribution2

100mcg of extrafine beclometasone in Fostair is equivalent to 250mcg of non-extrafine beclometasone2

For additional information to share with your patients who have been prescribed Fostair NEXThaler or Fostair pMDI please visit our Fostair NEXThaler patient and carer site or Fostair pMDI patient and carer site.

Click here for Fostair® (beclometasone/formoterol) Prescribing Information.

Fostair 100/6 is indicated for symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.1,2

COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 second; pMDI: pressurised metered dose inhaler.

References:
1. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
2. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Ltd on 0800 0092329 (UK), 1800 817459 (IE) PV.UK@Chiesi.com.